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Vascular smooth muscle cell (VSMC) function is regulated by Nox‑derived reactive oxygen species 
(ROS) and redox‑dependent signaling in discrete cellular compartments. Whether cholesterol‑rich 
microdomains (lipid rafts/caveolae) are involved in these processes is unclear. Here we examined 
the sub‑cellular compartmentalization of Nox isoforms in lipid rafts/caveolae and assessed the role 
of these microdomains in VSMC ROS production and pro‑contractile and growth signaling. Intact 
small arteries and primary VSMCs from humans were studied. Vessels from Cav‑1−/− mice were used 
to test proof of concept. Human VSMCs express Nox1, Nox4, Nox5 and Cav‑1. Cell fractionation 
studies showed that Nox1 and Nox5 but not Nox4, localize in cholesterol‑rich fractions in VSMCs. 
Angiotensin II (Ang II) stimulation induced trafficking into and out of lipid rafts/caveolae for Nox1 
and Nox5 respectively. Co‑immunoprecipitation studies showed interactions between Cav‑1/Nox1 
but not Cav‑1/Nox5. Lipid raft/caveolae disruptors (methyl‑β‑cyclodextrin (MCD) and Nystatin) and 
Ang II stimulation variably increased  O2− generation and phosphorylation of MLC20, Ezrin‑Radixin‑
Moesin (ERM) and p53 but not ERK1/2, effects recapitulated in Cav‑1 silenced (siRNA) VSMCs. 
Nox inhibition prevented Ang II‑induced phosphorylation of signaling molecules, specifically, 
ERK1/2 phosphorylation was attenuated by mellitin (Nox5 inhibitor) and Nox5 siRNA, while p53 
phosphorylation was inhibited by NoxA1ds (Nox1 inhibitor). Ang II increased oxidation of DJ1, dual 
anti‑oxidant and signaling molecule, through lipid raft/caveolae‑dependent processes. Vessels 
from Cav‑1−/− mice exhibited increased  O2− generation and phosphorylation of ERM. We identify an 
important role for lipid rafts/caveolae that act as signaling platforms for Nox1 and Nox5 but not Nox4, 
in human VSMCs. Disruption of these microdomains promotes oxidative stress and Nox isoform‑
specific redox signalling important in vascular dysfunction associated with cardiovascular diseases.
Vascular smooth muscle cell (VSMC) function is regulated by vasoactive factors that signal through multiple 
membrane-associated receptors and downstream signalling molecules, including kinases, phosphatases, ion 
channels and transcription factors. Many of these processes are influenced by reactive oxygen species (ROS), 
particularly superoxide  (O2−) and hydrogen peroxide  (H2O2), and involve post-translational modification of 
signalling proteins, including oxidation and  phosphorylation1, 2. Fundamental to these events is efficient orches-
tration and co-localization of signalling elements, which may involve plasma membrane cholesterol-rich micro-
domains that concentrate numerous receptors, G-proteins, and downstream molecules that function as effectors 
of extracellular  signals3, 4.
Cholesterol-rich microdomains, enriched in cholesterol and sphingolipids, comprise lipid rafts and caveolae 
and are abundant in endothelial cells and VSMCs. Lipid rafts/caveolae act as platforms for several signalling path-
ways that control VSMC function. Caveolae are specialized sub-types of lipid rafts with a similar lipid profile but 
they also contain the scaffolding protein caveolin (Cav), of which there are 3 isoforms (Cav-1–3) (21–24 kDA)5. 
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Of the Cav isoforms, Cav-1 is the most important for caveolae formation and function in VSMCs as demonstrated 
in Cav-1−/− mice where VSMC caveolae are absent and caveolae-associated signalling is  altered6. In particular 
cell proliferation is increased, eNOS is upregulated and vascular tone is  impaired7. Cav-1 contains a scaffolding 
domain that interacts with several proteins in microdomains and regulates their activation or  inhibition8. It also 
influences Ang II/ Ang II type 1 receptor (AT1R) signalling and trafficking, critically important in the regulation 
of VSMC function and vascular  contraction9, 10.
In addition to acting as a platform for classical signalling pathways, growing evidence indicates that lipid 
rafts/caveolae play a regulatory role in ROS generation. Cav-1 knock-down or cholesterol depletion by methyl-
β-cyclodextrin (MCD) in human lung fibroblasts and mouse macrophages leads to increased  O2− and  H2O2 
 generation11. Cav-1 knockdown by siRNA in bovine aortic endothelial cells promotes increased mitochondrial 
ROS generation and in aortic endothelial cells from Cav-1null mice  H2O2 levels are  increased12. Cav-1 silenc-
ing in VSMCs enhanced both basal and Ang II-induced mitochondrial ROS  generation13. These phenomena 
are especially important in VSMCs, where redox-dependent signalling is involved in almost every functional 
vascular response. Molecular mechanisms regulating vascular redox signalling are complex because different 
types of ROS influence different downstream pathways. For example,  O2− is important in pro-contractile14, 15 and 
pro-inflammaory  signalling16, whereas  H2O2 promotes  vasodilation17, 18. Processes controlling these differential 
responses may relate to sub-cellular compartmentalization of Noxs, the oxidases responsible for ROS generation 
in the vascular system.
Human vascular cells possess multiple Nox isoforms (Nox1, 2, 4, 5)19, 20, which have different functions in 
the vascular system: Nox1 promotes inflammation and  proliferation19, 20, Nox2 induces inflammation, Nox4 is 
vasoprotective 21, 22 and Nox5 is pro-contractile23, 24. Nox1-4 require p22phox for their activation while Nox5 is 
a p22phox-independent  isoform19–24 . Nox1, 2 and 5 are tightly regulated by vasoactive factors, whereas Nox4 is 
constitutively  active19–22. Molecular mechanisms responsible for these variable processes are unclear, although 
compartmentalization in sub-cellular domains including lipid rafts has been  suggested3, 11.
Other factors that modulate vascular ROS bioavailabity in VSMCs are antioxidant systems such as superoxide 
dismutase (SOD), catalase and peroxidases. In addition, PARK7 (Parkinson’s disease protein-7), also called DJ1, 
acts as an antioxidant and a signaling molecule. In its oxidized state, it activates nuclear factor erythroid-related 
factor 2 (Nrf2), a master regulator of anti-oxidant transcription  factors25, 26. DJ1 localizes in the cytoplasm and 
in conditions of oxidative stress translocates to the mitochondria and  nucleus27–29. It has also been shown to 
associate with Cav-1 in rat astrocytes and ventricular  cardiomyocytes30–32. However it is unknown whether DJ1 
associates with Noxs and Ang II signaling in VSMCs.
To better understand subcellular mechanisms that coordinate redox signaling we questioned the role of 
cholesterol-rich microdomains in Nox isoform regulation and ROS production and sought to evaluate whether 
these processes influence downstream redox-sensitive targets and pro-contractile and proliferative signaling in 
human VSMCs and vessels.
Results
Expression of Nox isoforms and localization with Cav‑1 in human small arteries. Cellular 
expression of Nox isoforms and co-localization with Cav-1 in intact human small arteries was assessed using 
double-labelling immunofluorescence. As shown in Fig. 1, Nox isoforms and Cav-1 are present in human arter-
ies. Cav-1 localized mainly in the endothelium (intima) and vascular smooth muscle (media) layer. Nox5 was 
expressed both in the endothelium and vascular media, with greater abundance in the vascular smooth muscle 
layer. Nox4 was expressed both in the endothelium and vascular smooth muscle layer. As shown in Fig. 1A,B, 
there is a partial colocalization of Nox5 and Cav-1 as indicated by the orange colour. Nox4 does not seem to 
localize with Cav-1. We could not detect Nox1 in whole tissue in an isoform-specific manner by immunofluo-
rescence despite multiple antibodies.
Nox 1 and Nox5, but not Nox4, associate with cholesterol‑rich microdomains in human 
VSMCs. To evaluate in greater detail the sub-cellular localization of vascular Nox isoforms in cholesterol-
rich microdomains and the impact of Ang II stimulation, we studied human VSMCs that were fractionated into 
cholesterol-rich and cholesterol-poor fractions using a detergent-free sucrose gradient centrifugation method. 
As shown in Fig. 2A, Nox5 was expressed in fractions 3–4, corresponding to cholesterol-rich fractions and which 
likely comprise lipid rafts/caveolae as confirmed by abundant Cav-1 expression. Nox5 was also present in the 
high density non-lipid raft fractions (fractions 7–12), possibly reflecting cytoplasmic localization. In subsequent 
studies, we combined lipid rich (fractions 3, 4) and non lipid-rich (fractions 7–12) fractions and showed that 
while Nox1 and Nox5 are expressed in both lipid-raft and high density non-lipid rafts fractions, abundance of 
Nox1 and Nox5 was greater in the high density versus the the low density fractions (Fig. 2B–D). Nox4 was abun-
dantly expressed in high density non-lipid fractions and absent in low density fractions, suggesting that Nox4, 
while expressed in VSMCs, does not localize in cholesterol-rich microdomains (Fig. 2E). These findings support 
those of others who also failed to show Nox4 in lipid rafts in VSMCs and endothelial  cells3, 11.
Ang II stimulates lipid raft/caveoale trafficking of Nox1 and Nox5 but not Nox1. As shown in 
Fig. 2B,C, Ang II stimulation resulted in rapid translocation of Nox5 (within 5 min) out of the lipid-raft fractions 
into the high density non-lipid raft fractions. On the other hand, Ang II stimulation induced Nox1 trafficking 
into lipid raft fractions (Fig. 2D). Ang II did not have any effect on Nox4 lipid-raft trafficking.
Cholesterol‑rich microdomains negatively regulate Nox‑derived superoxide production in 
human VSMC. To examine the functional significance of lipid rafts/caveolae in Nox-derived ROS produc-
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tion in basal and Ang II-stimulated VSMCs, we examined generation of  O2− and  H2O2 in Ang II-stimulated 
cells treated with or without MCD or nystatin. In basal conditions VSMCs exposed to MCD exhibited signifi-
cantly increased NADPH-derived  O2− levels compared with vehicle-treated cells in which lipid rafts were intact 
(Fig. 3A). Ang II significantly increased NADPH-derived  O2− production compared with basal conditions. Ang 
II increased  O2− production in Nys-treated VSMCs (Fig. 3A). Lipid-raft disruption by MCD or Nys did not 
have an effect on  H2O2 levels in human VSMCs (Fig. 3B). Together these results suggest that Noxs that generate 
primarily  O2−, including Nox1 and Nox5, are likley more tightly regulated by lipid rafts/caveolae than Noxs that 
generate mainly  H2O2, specifically Nox4.
Ang II‑induced generation of  O2− and  H2O2 in human VSMCs involves different Nox iso‑
forms. NADPH-dependent  O2− generation and  H2O2 levels were assessed in Ang II-stimulated VSMCs in 
the absence and presence of Nox isoform inhibitors. As shown in Fig. 4 Ang II induced an increase in NADPH-
dependent  O2− generation and  H2O2 within 5 min of stimulation. NoxA1ds, GKT137831 and mellitin reduced 
Ang II induced  O2− generation at variable time points (Fig. 4A). Ang II-stimulated increase in  H2O2 levels was 
reduced only by the Nox4 inhibitor GKT137831 (Fig. 4B). These data further support our findings that Nox1 
and Nox5, which localise in cholesterol-rich domains, play an important role in Ang II-stimulated  O2− produc-
tion, whereas Nox4, localised mainly in the cytoplasmic milieu, regulates  H2O2 generation in response to Ang II.
Disruption of cholesterol‑rich microdomains upregulates vascular redox signalling. To 
investigate whether cholesterol-rich microdomains influence redox-sensitive signal transduction in VSMCs, 
we examined signalling molecules involved in contraction (MLC20), actin cytoskeletal organization (Ezrin–
Radixin–Moesin), apoptosis/cell cycle (p53) and growth (ERK1/2) in Ang II-stimulated VSMCs in the absence 
and presence of MCD and nystatin. As shown in Fig.  5, within 5  min of stimulation, Ang II significantly 
increased phosphorylation of MLC20 (Ang II 5′: 275.0 ± 47.04% vs. Veh; Ang II 15′: 363.7 ± 121.2% vs. Veh; 
p < 0.05, Fig. 5A), Ezrin-Radixin-Moesin (Ang II 5′: 346.1 ± 119.0% vs. Veh; Ang II 15′: 260.1 ± 67.82% vs. Veh; 
p < 0.05, Fig. 5B), p53 (Ang II 5′: 133.5 ± 8.210% vs. Veh; Ang II 15′:149.9 ± 10.68% vs. Veh; p < 0.05, Fig. 5C) 
and ERK1/2 (Ang II 5′: 189.6 ± 37.23% vs. Veh; p < 0.05, Fig.  5D). Lipid raft disruptors, MCD and nystatin, 
increased expression of phospho-MLC20 (MCD: 329.9 ± 97.77% vs. Veh; MCD, Ang II 5′:341.5 ± 109.6% vs. Veh; 
Nys: 257.8 ± 75.89%; Nys, Ang II 15′: 372.3 ± 111.1% vs. Veh; p < 0.05, Fig. 5A), phospho-Ezrin-Radixin-Moesin 
(MCD, Ang II 5′: 474.5 ± 137.5, p < 0.05, Fig.  5B) and phospho-p53 (MCD: 128.4 ± 12.25% vs. Veh; p < 0.05, 
Figure 1.  Localization of Nox isoforms and caveolin-1 (Cav-1) in humans small arteries. Paraffin-
embedded sections of human small arteries were immunostained with Nox4, Nox5 and Cav-1. (A) Nox5 
partially colocalizes with Cav-1 in the vascular media. (B) Nox4 does not collocalize with Cav-1. Green 
immunofluorescence indicates Nox4 or Nox5 immunostaining, red indicates Cav-1 staining and blue indicates 
nuclear staining using DAPI. After probing with the respective antibodies, slides were mounted, images were 
recorded in an Axiovert 200M microscope with a laser scanning module LSM 510 (Carl Zeiss AG, Heidelberg, 
Germany) using a × 40 objective. Image processing was obtained by Image J. Asterisk: vascular media 
comprising VSMCs. Arrows: Endothelium. Arrowhead: partial-colocalization of Nox5 and Cav-1 (orange 
colour). Cav-1 Caveolin-1, IgG immunoglobulin G.
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Figure 2.  Nox1 and Nox5 but not Nox4 are present in lipid-rafts/caveolae in human VSMCs. VSMCs isolated 
from small arteries were stimulated with Ang II and subjected to discontinuous sucrose density gradient. (A) 
Representative immunoblots of Nox5 and Cav-1. Nox5 is present in isolated lipid-rafts fractions 3–4 in human 
VSMCs. (B) Representative images of Nox5 and Nox1 in lipid rafts (LRs) vs. non-lipid rafts (NLRs) in VSMCs 
stimulated with Ang II (100 nmol/L) for 5, 15 or 30 min. Isolated LR (fractions 3–4) or high density NLR 
(fractions 7–12) were pooled together and the percentage ratio of LRs vs. NLRs for Nox5 (C) and Nox1 (D) 
was determined. (E) Representative images of Nox4 in LRs vs. NLRs. Bar graphs are means ± SEM from 4–5 
experiments. Control was taken as 100% and data are presented as the percentage changes relative to control 
conditions. *P < 0.05 vs. Ctl. #P < 0.05 vs. Ang II, 5 min. Ang II angiotensin II, Ctl control, Cav-1 caveolin-1, 
LR lipid rafts, NLR non-lipid rafts, M marker, THP1 human acute monocytic leukemia cells, VSMCs vascular 
smooth muscle cells.
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Fig. 5C). No additional effects of Ang II were observed. Cholesterol reloading prevented phosphorylation of 
MLC20 and Ezrin–Radisin–Moesin in MCD-treated cells.
Nox isoforms differentially regulate Ang II signaling. We used two approaches to interrogate 
the role of Nox isoforms in Ang II signaling, (1) pharmacological inhibitors and (2) siRNA targeting. Cells 
were pretreated with Nox isoform-specific pharmacological inhibitors including NoxA1ds (Nox1 inhibitor), 
GKT137831 (Nox1/4 inhibitor) and melittin (Nox5 inhibitor). These inhibitors have been extensively used and 
well  characterised33–35. As shown in Fig. 6 after 5 min of stimulation, Ang II significantly increased phospho-
rylation of MLC20, Ezrin-Radixin-Moesin, ERK1/2 and, p53. GKT137831 and mellitin significantly reduced 
Ang II-induced phosphorylation of MLC (Fig. 6A) and Ezrin-Radixin-Moesin (Fig. 6B). NoxA1ds and mellitin 
significantly inhibited ERK1/2 phosphorylation (Fig. 6C) while p53 phosphorylation was attenuated only by 
NoxA1ds (Fig. 6D).
To specifically investigate the effects of Nox5 on Ang II-induced ROS production and redox signaling, cells 
were transfected with Nox5 siRNA (Supplementary figure 1A). In basal conditions, Nox5 silencing did not sig-
nificantly alter  O2− levels (Fig. 7A), but increased  H2O2 levels (Fig. 7B, Nox5 siRNA 63.3 ± 27.69% increase vs. 
Control, p < 0.05) compared to control siRNA. In Nox5 downregulated cells, Ang II failed to increase  O2− and 
had no effect on  H2O2 production.
Nox5 silencing differentially influenced Ang II signaling in VSMC as shown in Fig. 7C–F. Nox5 downregula-
tion did not alter phosphorylation of Ezrin/Radixin/Moesin, p-53 and ERK1/2 in basal conditions. In control 
siRNA cells, Ang II stimulation induced a significant increase in phosphorylation of Ezrin/Radixin/Moesin, 
p-53 and ERK1/2 compared with control counterparts. In Nox5 siRNA-treated cells, Ang II failed to increase 
phosphorylation of target proteins compared with control counterparts. Ang II-induced activation of ERK1/2 
was significantly lower in Nox5 siRNA cells versus control siRNA cells (Nox5 siRNA 89.5 ± 9.56% increase vs. 
Control 193 ± 33.2%, p < 0.05).
Figure 3.  Differential effects of lipid-raft disruption on Ang II–induced ROS production. VSMCs were 
treated with methyl-b-cyclodextrin (MCD; 10 mmol/L) for 45 min or Nystatin (Nys; 50 μg/mL) for 30 min 
and stimulated with Ang II (100 nmol/L) for 5 and 15 min. (A) NADPH-derived  O2− generation measured 
by lucigenin assay in human VSMCs. (B)  H2O2 levels were measured by the Amplex Red assay. Data are 
mean ± SEM from 5–12 experiments. Control was taken as 100% and data are presented as the percentage 
changes relative to control conditions. *P < 0.05 vs. Ctl. Ang II angiotensin II, Ctl control, H2O2 hydrogen 
peroxide, RLU relative light units.
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To investigate the role of of Nox1–4 (p22phox-dependent Nox isoforms) in Ang II-induced signaling, p22phox 
was silenced in VSMCs using siRNA (Supplementary figure 2A). In basal conditions, p22phox silencing increased 
production of  O2− (Fig. 8A, p22phox siRNA 63.3 ± 27.69% increase vs. Control, p < 0.05) and  H2O2 in hVSMC 
(Fig. 8B, p22phox siRNA 23.5 ± 7.84% increase vs. Control, p < 0.05). Ang II did not cause a further increase in 
 O2− or  H2O2 levels in cells transfected with p22phox siRNA.
Silencing of p22phox influenced Ang II signaling in VSMCs as shown in Fig. 8C–F. In p22phox siRNA-treated 
cells, basal levels of phosphorylated Ezrin/Radixin/Moesin (p22phox siRNA 69.7 ± 29.57% increase vs. Control, 
p < 0.05) and p53 (p22phox siRNA 44.7 ± 21.54% increase vs. Control, p < 0.05) were increased. In contrast, basal 
and Ang II-induced ERK1/2 phosphorylation was not affected by p22phox silencing compared to control siRNA.
Ang II influences redox regulation of DJ1 in human VSMCs. To investigate whether other redox-
sensitive targets important in vascular cell function are influenced by the lipid rafts/caveolae-Nox system, we 
investgated effects on DJ1, a dual antioxidant and signaling molecule, that we found to be abundantly expressed 
in human small arteries (Supplementary figure 2) and which interacts with Cav-1 and Nox1 (Supplementary 
figure 3). As shown in Supplementary figures 3A–2C, DJ1 physically associated with Nox1 but not with Nox5. 
Interactions between DJ1 and Nox1 were also observed by immunofluorescence, where Nox1 and DJ1 co-local-
ized in VSMCs as shown in Supplemental figure 2D by the yellow fluorescence in merged images.
Having demonstrated that human vessels and VSMCs abundantly express DJ1, we questioned whether Ang 
II regulates redox-sensitive (oxidized) DJ1 through prcesses involving cholesterol-rich microdomains. Human 
VSMCs were probed with specific antibodies against total and irreversibly oxidised DJ1 (Cys 106-SO2H; Cys 
106-SO3H). DJ1 expression was examined in isolated lipid-rafts and non-lipid raft fractions of VSMCs stimulated 
Figure 4.  Nox isoforms differentially regulate Ang II-induced ROS production in human VSMC. Cells were 
stimulated with Ang II (100 nmol/L) for 5 and 15 min in the presence and absence of NoxA1ds (Nox1 inhibitor, 
10 μmol/L), GKT137831 (Nox1/Nox4 inhibitor, 10 μmol/L) and melittin (Nox5 inhibitor, 100 nmol/L). NADPH 
dependent  O2− production (A) and  H2O2 levels (B) were measured by lucigenin-derived chemiluminescence 
and amplex red, respectively. Results are expressed as mean ± SEM of 6–8 separate experiments. *P < 0.05 vs. Ctl, 
+P < 0.05 vs. respective Ang II group. Ang II angiotensin II, Ctl control, H2O2 hydrogen peroxide, RLU relative 
light units.
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with or without Ang II  (10−7 M) for 5 min. As shown in Fig. 9A, the irreversibly oxidised form of DJ1 was only 
present in non-lipid raft fractions even though total DJ1 was present in lipid-rafts. These findings indicate that 
either non-oxidised or only reversibly oxidised DJ1 is present in rafts. Ang II increased irreversible oxidation of 
DJ1 within 5 min (Ang II 5′: 125.8 ± 3.870% vs. Veh, Ang II 15′: 134.8 ± 10.17% vs. Veh; p < 0.005) as shown in 
Fig. 9B. Lipid-raft disruption by MCD or nystatin induced an increase of irreversible oxidation of DJ1, a trend 
that did not reach statistical significance. The irreversibly oxidized form of DJ1 represents increased activation 
of DJ1 and identifies a novel downstream signaling target of Ang II.
Cav‑1 silencing increases ROS production and redox signaling in hVSMC. To further investigate 
the relationship between lipid rafts/caveolae, ROS and Ang II-induced signaling, we investigated effects of Cav-1 
silencing (with siRNA; Supplementary figure 4) on ROS generation and Ang II-mediated redox signaling in 
hVSMC. As shown in Fig. 10A, in basal conditions, Cav-1 silencing resulted in an increase in NADPH-depend-
ent  O2− levels compared to control siRNA (Cav-1siRNA 108.06 ± 33.98% increase vs. Control, p < 0.05). A similar 
response was observed for  H2O2 (Fig. 10B), since cells transfected with Cav-1 siRNA showed higher  H2O2 levels 
compared to control (Cav-1siRNA 165.3 ± 22.39% increase vs. Control, p < 0.05). Ang II did not cause a further 
increase in NADPH-dependent  O2− or  H2O2 levels in Cav-1 siRNA-treated cells.
In addition to impacting ROS production, Cav-1 silencing influenced signaling in hVSMCs as shown in 
Fig. 10C–F. Cav-1 downregulation resulted in an increase in basal levels of phospho-Ezrin/Radixin/Moesin and 
phospho-p53 but not ERK1/2. In Ang II-stimulated cells, phosphorylation of ERK1/2, but not Ezrin/Radixin/
Moesin or phospho-p53, was increased.
ROS generation and redox‑sensitive signalling are increased in arteries from caveolin‑1−/− 
mice. To test proof of concept from our human studies, we investigated whether our in  vitro findings in 
Figure 5.  Effect of lipid-raft disrupters on phosphorylation of MLC20, Ezrin/Radixin/Moesin, p53 and ERK1/2 
in Ang II-stimulated human VSMCs. VSMCs were stimulated with Ang II (100 nmol/L) for 5 and 15 min in the 
presence and absence of MCD (10 mmol/L) or Nys (50 μg/mL). In some experiments, after MCD treatment, 
cholesterol was reloaded with cholesterol:MCD (1–10 mmol/L) complex. Phosphorylation of MLC20 (A), 
Ezrin–Radixin–Moesin (B), p53 (C) and ERK1/2 (D) were analysed by western blot. β-Actin was used as 
loading control. Bar graphs are means ± SEM from 5–7 experiments. Control was taken as 100% and data are 
presented as the percentage changes relative to control conditions. *P < 0.05 vs. Ctl. Ang II angiotensin II, Ctl 
control, MCD methyl-b-cyclodextrin, Nys nystatin, Chol cholesterol, p-MLC20 phosphorylated MLC20, p-ERM 
phosphorylated Ezrin–Radixin–Moesin, p-p53 phosphorylated p53, p-ERK1/2 phosphorylated ERK1/2.
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human VSMCs are recapitulated in intact arteries in  vivo. We studied isolated arteries from wild-type, and 
Cav-1−/− mice and probed for Nox-dependent  O2− production and activation of redox-sensitive signalling path-
ways, ERK1/2 and Ezrin-Radixin-moisin. As shown in Fig.  11A, mesenteric arteries isolated from Cav-1−/− 
mice had significantly higher levels of NADPH-dependent  O2− levels compared to wild-type mice (Cav-1−/−, 
443.02 ± 131.70% increase vs. Control, p < 0.05). Aortas isolated from Cav-1−/− mice had significantly greater 
expression of phospho-Ezrin/Radixin/Moesin compared with control mice while ERK1/2 phosphorylation was 
not significantly altered between groups (Fig. 11B). These findings suggest that in the absence of regulated cave-
olae (Cav-1−/−), Nox-dependent ROS production and activation of signalling pathways associated with VSMC 
actin cytoskeletal organisation are increased, indicating an important role for intact lipid rafts/caveolae (Cav-
1) in the regulation of Nox activity, ROS generation and vascular signalling, findings recapitulated in human 
VSMCs.
Discussion
Vascular signalling is mediated in large part through Nox-derived ROS and activation of redox-sensitive path-
ways that regulate VSMC function. Sub-cellular mechanisms underlying these processes have not been fully 
elucidated but compartmentalization in cholesterol-rich microdomains may be important. This is especially 
relevant for Ang II since the  AT1R and associated signalling molecules localize in lipid rafts/caveolae. In the 
present study, using a multidisciplinary approach, we identify these microdomains as an important structural 
element in Nox-ROS regulation and redox-dependent signalling in human VSMCs and show that disruption of 
these microdomains promotes oxidative stress and aberrant vascular signalling. Our findings demonstrate that 
these processes are highly regulated and Nox isoform-specific since Nox1 and Nox5, but not Nox4, localize in 
lipid rafts/caveolae, which when disrupted lead to increased Nox-derived ROS production and hyperactivation of 
signalling pathways important in VSMC function including, MLC20, Ezrin–Radixin–Moesin and p53 involved 
in contraction, cytoskeletal organization and apoptosis/cell cycle control respectively. In addition, we identified 
DJ1 as a redox-sensitive downstream target regulated by Ang II in a Nox- and lipid raft/caveolae-dependent man-
ner. To recapitulate our findings in human VSMCs in an intact system, we studied mice deficient in Cav-1 and 
caveolae and demonstrated that Nox-derived ROS and vascular signalling are exaggerated. Together our findings 
identify an important role for cholesterol-rich microdomains that act as regulatory elements for Nox1 and Nox5 
and redox-sensitive signalling platforms in VSMCs (Fig. 12). Loss of integrity of these microdomains promotes 
oxidative stress and altered signaling, important in vascular dysfunction associated with pathological processes.
Figure 6.  Nox1, Nox4 and Nox5 are involved in Ang II-induced redox signalling in human VSMC. Cells 
were stimulated with Ang II, (100 nmol/L) for 5 and 15 min in the presence and absence of NoxA1ds (Nox1 
inhibitor, 10 μmol/L), GKT137831 (Nox1 and Nox4 inhibitor, 10 μmol/L) and melittin (Nox5 inhibitor, 
10 nmol/L). Phosphorylation of MLC (A), Ezrin-Radixin-Moesin (B), p53 (C) and ERK1/2 (D) was detected by 
western blotting in hVSMC. α-Tubulin and total ERK1/2 were used as loading control. Results are expressed as 
mean ± SEM of 6–8 separate experiments. *P < 0.05 vs. control (Ctl), +P < 0.05 vs. respective Ang II group. Ang II 
angiotensin II, Ctl control, p-MLC20 phosphorylated MLC20, p-ERM phosphorylated Ezrin–Radixin–Moesin, 
p-p53 phosphorylated p53, p-ERK1/2 phosphorylated ERK1/2.
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Figure 7.  Effect of Nox5 silencing on ROS production and Ang II-induced signaling in hVSMC. Cells were 
transfected with Nox5 or control (Ctl) siRNA and stimulated with Ang II (100 nmol/L) for 5 min. NADPH-
derived  O2− generation was measured by lucigenin assay (A).  H2O2 levels were measured by the Amplex Red 
assay (B). Representaive images of phospho-Ezrin–Radixin–Moesin, phospho-p53, phospho-ERK1/2 and Nox5 
detected by western blot. α-tubulin and total ERK1/2 were used as loading control (C). Protein quantification of 
Ezrin–Radixin–Moesin (D), p53 (E) and ERK1/2 (F) phosphorylation in hVSMCs. Data are means ± SEM from 
4–7 experiments. Control was taken as 100% and data are presented as the percentage changes relative to control 
conditions. *P < 0.05 vs. control, +P < 0.05 vs. AngII Ctl siRNA. Ang II angiotensin II, Ctl control, H2O2 hydrogen 
peroxide, RLU relative light units, p-MLC20 phosphorylated MLC20, p-ERM phosphorylated Ezrin–Radixin–
Moesin, p-p53 phosphorylated p53, p-ERK1/2 phosphorylated ERK1/2.
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Figure 8.  p22phox silencing effect on ROS production and Ang II-induced signaling in hVSMC. Cells were 
transfected with p22phox or control (Ctl) siRNA and stimulated with Ang II (100 nmol/L) for 5 min. NADPH-
derived  O2− generation was measured by lucigenin assay (A).  H2O2 levels were measured by the Amplex Red 
assay (B). Representaive images of phospho-Ezrin–Radixin–Moesin, phospho-p53, phospho-ERK1/2 and 
p22phox detected by western blot. α-Tubulin and total ERK1/2 were used as loading control (C). Protein 
quantification of Ezrin–Radixin–Moesin (D), p53 (E) and ERK1/2 (F) phosphorylation in hVSMCs. Data 
are means ± SEM from 4–7 experiments. Control was taken as 100% and data are presented as the percentage 
changes relative to control conditions. *P < 0.05 vs. control, +P < 0.05 vs. AngII Ctl siRNA. Ang II angiotensin 
II, Ctl control, H2O2 hydrogen peroxide, RLU relative light units, p-MLC20 phosphorylated MLC20, p-ERM 
phosphorylated Ezrin–Radixin–Moesin, p-p53 phosphorylated p53, p-ERK1/2 phosphorylated ERK1/2.
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Noxs are widely recognised as key sources of ROS in vascular cells that play a crucial role in the progression of 
cardiovascular  diseases36, 37. Despite advances in redox research, molecular mechanisms regulating Nox activity 
and their compartmentalization in the vascular system, especially in human VSMCs, is still poorly defined. This 
is particular relevant for Nox5, where progress has been slow due to the lack of research tools and experimental 
models, as NOX5 gene is not expressed in rodents, the major experimental model used to study cardiovascular 
Nox biology. Although it has been proposed that Nox and ROS compartmentalize in different cellular organelles, 
including mitochondria and endoplasmic  reticulum38, 39, where distinct redox signaling is tightly controlled, 
the role of cholesterol-rich microdomains remains unclear, particularly in the human context. Previous studies 
using qualitative approaches showed Nox1 in caveolae in human  VSMCs3. In lung fibroblasts and heterologous 
expression systems in COS-7 expressing Cav-1/Nox5, Cav-1/Nox2, Cav-1/Nox411, Nox2 and Nox5, but not 
Nox4, were found to associate with lipid-rafts through direct interactions with Cav-1. Using multiple approaches 
Figure 9.  DJ1 oxidation—effects of Ang II and lipid raft disruptors. VSMCs treated with Ang II were subjected 
to discontinuous sucrose density gradient. (A) Representative immunoblots of total and irreversibly oxidised 
DJ1 in lipid rafts (LRs) vs. non-lipid rafts (NLRs). (B) VSMCs were stimulated with Ang II (100 nmol/L, 5 and 
15 min) or treated with lipid-raft disruptors (10 mmol/L MCD or 50 μg/mL Nys). Representative immunoblots 
and quantification of total and irreversible oxidised DJ1. β-Actin was used as loading control. Data are 
means ± SEM from 7 experiments. Control was taken as 100% and data are presented as the percentage changes 
relative to control conditions. *P < 0.05 vs. control. Ang II angiotensin II, Ctl control, Cav-1 caveolin-1, LR lipid 
raft, NLR non-lipid raft, M marker, MCD methyl-b-cyclodextrin, Nys nystatin.
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Figure 10.  Cav-1 silencing increases ROS production and redox signaling in hVSMC. Cells were transfected 
with Cav-1 or control (Ctl) siRNA and stimulated with Ang II (100 nmol/L) for 5 min. NADPH-derived 
 O2− generation measured by lucigenin assay (A).  H2O2 levels were measured by the Amplex Red assay (B). 
Representaive images of phospho-Ezrin–Radixin–Moesin, phospho-p53, phospho-ERK1/2 and Cav-1 
detected by western blot. α-tubulin and total ERK1/2 were used as loading control (C). Protein quantification 
of Ezrin–Radixin–Moesin (D), p53 (E) and ERK1/2 (F) phosphorylation in hVSMCs. Data are means ± SEM 
from 6–8 experiments. Control was taken as 100% and data are presented as the percentage changes relative 
to control conditions. *P < 0.05 vs. control, +P < 0.05 vs. AngII Ctl siRNA. Cav-1 caveolin-1, Ang II angiotensin 
II, Ctl control, H2O2 hydrogen peroxide, RLU relative light units, p-MLC20 phosphorylated MLC20, p-ERM 
phosphorylated Ezrin–Radixin–Moesin, p-p53 phosphorylated p53, p-ERK1/2 phosphorylated ERK1/2.
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Figure 11.  ROS generation and vascular signaling in Cav-1-deficient mice. Wild type (WT) and Cav-1−/− mice 
were infused with vehicle (Veh; saline) or Ang II (400 ng/kg/min) and after two weeks, mesenteric arteries 
and aortas were isolated for NADPH-dependent ROS generation measurement and protein expression. (A) 
NADPH-derived  O2− generation measured by lucigenin assay in mesenteric arteries. (B) Phosphorylation of 
Ezrin/Radixin/Moesin and ERK1/2 in aortas isolated from WT and Cav-1−/− mice. β-Actin was used as loading 
control. Data are means ± SEM from 5–7 experiments. *P < 0.05 vs. WT. Ang II angiotensin II, Cav-1 caveolin-1, 
Cav-1−/− caveolin-1 deficiency, Veh vehicle, RLU relative light units, p-ERM phosphorylated Ezrin–Radixin–
Moesin, p-ERK1/2 phosphorylated ERK1/2.
14
Vol:.(1234567890)
Scientific Reports |        (2020) 10:17818  | https://doi.org/10.1038/s41598-020-73751-4
www.nature.com/scientificreports/
including pharmacological inhibitors and siRNA to downregulate Nox isoforms, we show both qualitatively and 
quantitatively that in human VSMCs, Nox1 and Nox5, but not Nox4 are present in cholesterol-rich fractions 
and that redox signalng is differentially regulated by distinct Nox isoforms. To further confirm these findings we 
performed co-immunoprecipitation assays to examine whether Nox1 or Nox5 directly interact with Cav-1 and 
showed that Nox1 co-immunoprecipitates with Cav-1. Nox5, although present in cholesterol-rich microdomains, 
did not interact with Cav-1, suggesting that it may associate with non-caveolae lipid fractions.
Reasons why cholesterol-rich microdomains are enriched in Nox1 and Nox5, but not Nox4, are unclear but 
might relate, at least in part, to different functions of these Nox isoforms. In particular, activation of Nox1 and 
Nox5 generate primarily  O2− whereas activation of Nox4 produces mainly  H2O240–43. This was corroborated in 
our studies in Nox5 downregulated cells, where Ang II stimulation increased production of  H2O2 but not  O2−. 
It may be possible then that  O2– generating Noxs localise in microdomains where they directly influence redox-
sensitive signaling molecules, while Nox4-generating  H2O2 localizes mainly in cholesterol-poor fractions, namely 
the cytoplasm. This differential compartmentalization may contribute to distinct  O2− versus  H2O2-mediated 
signaling in VSMCs. This is relevant because these reactive species influence different signalling pathways with 
variable functional responses. For example,  O2− is associated with vasoconstriction, whereas  H2O2 contributes to 
basal redox status and promotes  vasodilation14, 15, 17, 18. Moreover processes of Nox regulation may be important 
because Nox1 and Nox5, localised in cholesterol-rich domains, are activated by vasoactive agents, whereas Nox4, 
which does not associate with lipid rafts/caveolae, is constitutively active.
Figure 12.  Schematic showing putative interactions between lipid rafts/caveolae, Nox isoforms, DJ-1 and 
vascular signaling in conditions where lipid rafts/caveolae are intact and when they are discrupted. (i) When 
cholesterol-rich microdomains are intact, likely in physiological conditions, Nox1 and Nox5 are regulated and 
ROS production is controlled. Nox4 which is constitutively active, localizes in the cytoplasm where it generates 
mainly  H2O2, which may be vasoprotective. (ii) During lipid-raft disruption, which may occur in pathological 
conditions or when the Ang II system is upregulated, Nox1 and Nox5 are activated leading to excessive 
ROS production and oxidative stress. This promotes increased redox-dependent signaling through multiple 
downstream pathways that influence VSMC function. P phosphorylation, Ox oxidation, MLC20 myosin light 
chain, ERM Ezrin–Radixin–Moesin.
15
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17818  | https://doi.org/10.1038/s41598-020-73751-4
www.nature.com/scientificreports/
Ang II signaling involves Nox-derived ROS as we previously  demonstrated1, 37. Considering the importance 
of lipid rafts/caveolae in Nox1/5-ROS regulation in VSMCs we questioned whether Ang II influences lipid raft/
caveolae trafficking of these Noxs. Within 5 min of Ang II stimulation, Nox1 shuffled from non-lipid raft frac-
tions to lipid-rich fractions, while Nox5 moved in the opposite direction, indicating that Ang II regulates Nox 
trafficking in a highly organized and isoform-specific manner. The significance of this may relate to the differ-
ential functions of Nox1 and Nox5. Nox1 is important in vascular inflammation and expression/activation of 
pro-inflammatory adhesion  molecules44–46, which associate with the cell membrane and lipid rafts/caveolae, while 
Nox5 is involved in VSMC contraction, proliferation and cytoskeletal  organization2, 23. To dissect out distinct 
roles for Nox1 and Nox5 in human VSMCs we used a multidisciplinary approach including various pharmaco-
logical inhibitors (NoxA1ds, GKT137831 and mellitin) and siRNA targeted to Nox5 and p22phox-dependent 
Noxs, which includes Nox1-Nox4. Our findings suggest that Noxs regulate multiple signaling pathways and that 
Nox5 seems to be especially important in Ang II-stimulated ERK1/2 signaling whereas Nox1 is involved in Ang 
II-induced activation of p53. These phenomena may contribute, at least in part, to the diverse vascular actions 
of Ang II. It should be highlighted that we assessed acute signaling events and that different Nox-dependent 
responses may occur with chronicstimulation.
Lipid-rafts/caveolae seem to play an important regulatory role in maintaining basal ROS production, because 
disruption of these microdomains or depletion of cholesterol, caused excessive ROS generation, processes that 
lead to oxidative stress, cell injury and vascular dysfunction. This is exemplified by our findings that in human 
VSMCs exposed to MCD and nystatin, Nox-derived ROS generation was increased, findings that were recapitu-
lated in Cav-1-silenced human VSMCs and vessels from Cav-1−/− mice. Similar responses have been observed in 
MCD-treated mouse macrophages, macrophages from Cav-1−/− mice and in human lung fibroblasts where Cav-1 
was knocked down by  siRNA11. These results together with our findings support the notion that cholesterol-rich 
microdomains are negative regulators of Nox-derived  O2− generation. While we can not distinguish exactly which 
Nox isoform is involved in this process, it is likely to be Nox1 and/or Nox5, but not Nox4 because Nox4 does not 
seem to be abundant in lipid-rafts and Nox4 generates primarily  H2O2.
Vascular signaling through lipid rafts/caveolae is highly selective. For example, phosphorylation of MLC20, 
Ezrin/Radixin/Moesin and p53, but not ERK1/2, was variably increased. ERK1/2 activation seems to be inde-
pendent of cholesterol microdomains in human VSMCs. This was corroborated in VSMCs in which Cav-1 was 
downregulated, since phosphorylation of Ezrin/Radixin/Moesin and p53, but not ERK1/2, was increased. These 
in vitro results are in agreement with intact vessels isolated from Cav-1−/− mice where phosphorylation levels 
of ERK1/2 were similar to vessels from wild-type mice. The importance of Cav-1 in ERK1/2 activation remains 
controversial, as previous studies showed that Cav-1 might have an inhibitory or stimulatory role depending on 
the cell type. In rat aortic VSMCs, cardiac fibroblasts, NIH 3T3 fibroblast and Rat-1 cells, regulation of ERK1/2 
activity is Cav-1-dependent47–50, whereas in bovine aortic endothelial cells and in mouse embryonic fibroblasts 
it seems to be Cav-1-independent7, 51. On the other hand, signalling pathways associated with cell contraction 
and cytoskeletal organisation in human VSMCs seem to be controlled by microdomain integrity, because lipid-
raft disruption induced phosphorylation of MLC20 in human VSMCs, a response that is Nox5-dependent as 
we previously  demonstrated23. The importance of lipid rafts/caveolae in the regulation of vascular contraction 
has been demonstrated in rat tail artery rings and rat cremaster  arterioles52, 53 and confirmed in aortic rings 
from Cav-1−/− mice, which exhibited reduced contractile responses to vasoconstrictive agents including Ang II, 
endothelin-1 and phorbol  ester6.
Cholesterol-rich microdomains interact with the cell cytoskeleton and are intricately involved in the organisa-
tion of the actin and its associated structural  proteins54. Cholesterol depletion promotes F-actin polymerisation 
and stress fibre formation in tumour  cells55, mesenchymal and epithelial cells while in fibroblasts MCD induces 
actin disassembly and reduction of stress  fibres56. In our study we showed that cholesterol-rich microdomains 
influence activation of the actin cytoskeleton- associated proteins, Ezrin/Radixin/Moesin, which act as cross-
linkers between plasma membranes and actin filaments. Phosphorylation of these proteins is necessary for its 
binding to the F-actin  cytoskeleton57, 58. We found that lipid-raft disruption and Cav-1 downregulation in human 
VSMCs was associated with increased phosphorylation of Ezrin/Radixin/Moesin indicating the importance 
of intact microdomains for cytoskeleton organization. These findings were further confirmed in intact vessels 
from Cav-1−/− mice.
Another signaling system regulated by lipid rafts/caveoale involves p53, a master transcriptional factor con-
trolling genes involved in cell cycle arrest, senescence or apoptosis. Phosphorylation of p53 at Ser15 and Ser20 
disrupts the interaction between p53 and its negative regulator MDM2, leading to the accumulation and activa-
tion of p53 in response to cellular stress-induced DNA  damage59, 60. We found that Ang II increased phospho-
rylation of p53 (Ser 15) in human VSMCs, similar to what has been shown in neonatal rat cardiomyocytes, H9c2 
 cells61 and rat aortic  cells62, 63. We also found that MCD increased phosphorylation of p53 (Ser 15) supporting 
a role for cholesterol-rich fractions in p53 regulation, similar to what was demonstrated in chicken myogenic 
 cells64, 65. To further support this notion, ROS-induced activation of p53 in fibroblasts from Cav-1−/− mice was 
 altered66, 67 and transient overexpression of Cav-1 in mouse NIH 3T3 fibroblasts or stable transgenic Cav-1 
expression in fibroblasts caused cell cycle arrest and  senescence68.
In addition to identifying a regulatory role for microdomains in Nox-ROS-redox signalling, we found that 
DJ1 is a caveolar-resident protein that interacts with Cav-1 and Nox1 in human VSMCs. DJ1 is increasingly 
being recognized as an important redox-sensitive molecule involved in vascular  regulation66–68. DJ1 acts as a ROS 
scavenger and also as a signaling protein that activates transcriptional factors, such as nuclear factor erythroid 
2-related factor 2 (Nrf-2)26, 69. The anti-oxidant function of DJ1 depends on its oxidation state of Cys-106, which is 
oxidised by ROS from sulfenic acid (Cys-SOH) to sulfinic acid (Cys-SO2H) to sulfonic acid (Cys-SO3H). Having 
observed that DJ1 is abundantly expressed in human arteries and VSMCs, we questioned whether DJ1 may be 
another redox-sensitive target regulated by Ang II through Nox-lipid raft/caveolae mechanisms. We found that 
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Ang II rapidly increased irreversible oxidation of DJ1 (Cys 106-SO2H; Cys 106-SO3H), but only in the non-lipid 
raft fraction. To our knowledge these are the first studies showing that Ang II regulates DJ1 in VSMCs through 
processes involving rafts and oxidation. The functional significance of this awaits clarification.
Similar to many other  studies70–74, we used a pharmacological approach to disrupt lipid rafts/caveolae in 
human VSMCs. However this approach does have limitations because MCD has been shown to disrupt choles-
terol-rich domains beyond the plasma  membrane70, 71. In particular MCD influences membranes of subcellular 
organelles, including mitochondria, and accordingly we can not exclude the potential role of other sources, such 
as mitochondria, for ROS in our experimental paradigm. To mitigate some of these limitatons, we used a second 
disrupter, nystatin to interrogate lipid rafts. Moreover we studied VSMCs in which Cav-1 was downregulated 
using siRNA approaches.
In conclusion, we demonstrate that Nox1 and Nox5 localize and traffic through cholesterol-rich microdo-
mains, which act as negative regulators for Nox-induced ROS generation and redox signaling in human VSMCs. 
Loss of integrity of cholesterol-rich microdomains promotes oxidative stress and alters signaling important in 
vascular dysfunction associated with cardiovascular disease. Our findings suggest that lipid rafts/caveolae are 
discrete sub-cellular compartments involved in Nox1 and Nox5-derived ROS generation and signaling in human 
VMSCs. This regulatory system is Nox isoform-specific because Nox4-derived  H2O2 seems to be independent 
of lipid rafts/caveolae.
Methods
Detailed methodology is provided in the Online Data Supplement.
Human vascular tissue and primary human vascular smooth muscle cell culture. All studies 
related to accessing small arteries and vascular smooth muscle cells (VSMCs) from humans were approved by 
the West of Scotland Research Ethics Service (WS/12/0294). Written informed consent was received from all 
study participants in accordance with the Declaration of Helsinki (1997). Human small arteries were obtained 
from patients undergoing elective craniofacial surgeries (n = 12) at the Queen Elizabeth University Hospital, 
Glasgow. A small piece of vascular tissue was fixed in 4% paraformaldehyde (PFA) overnight and used for 
immunofluorescence. The remaining tissue was used to isolate VMSCs by enzymatic digestion, as previously 
 described39, 75. Experiments were performed on low-passage cells (passage 4–6).
VSMCs were serum-deprived overnight and stimulated with 100 nmol/L Ang II for 5 and 15 min. In some 
studies, cells were pre-treated with lipid-raft disruptors methyl-β-cyclodextrin (MCD, 10 mmol/L, Sigma Aldrich, 
332615) for 45 min or Nystatin (Nys, 50 μg/mL, Sigma Aldrich, N3503) for 30 min and then stimulated with 
Ang II. To investigate the role of Noxs in VSMC signalling, cells were pre-treated (30 min) with NoxA1ds (Nox1 
inhibitor, 10 μmol/L, Merck 532759), GKT137831 (Nox1/NOX4 inhibitor, 10 μmol/L, Cambridge Bioscience 
CAY17764) or melittin (Nox5 inhibitor, 100 nmol/L; Sigma-Aldrich M2272). Concentrations used were based 
on previously published  data33–35, 39.
Immunofluorescence and immunohistochemistry staining of human small arteries. Immuno-
fluorescence of Nox5, Nox4, total DJ1 and Cav-1 and immunohistochemistry of irreversibly oxidized DJ1 (Cys-
SO2H and Cys-SO3H) was determined in human small arteries.
Isolation of cholesterol‑rich microdomain by protein fractionation using detergent‑free 
sucrose gradient centrifugation. Lipid-rafts/caveolae in VSMCs stimulated with/without Ang II for 5, 
15 or 30 min were isolated by protein fractionation using the detergent-free sucrose gradient centrifugation 
method as we previously  described73, 74. Fractionated proteins from VSMCs were separated by immunoblotting. 
In some experiments, isolated lipid-raft fractions (fractions 3–4) and non-lipid-raft fractions (7–12) were pooled 
together.
Cholesterol depletion/sequestration and cholesterol reloading. To disrupt caveolae in VSMCs, 
free cholesterol was depleted or sequestrated from the plasma membrane by using two different agents, MCD 
or Nys, respectively as previously  described74. Cholesterol was depleted by treating VSMCs with mM MCD for 
45 min at 37 °C. Cholesterol was sequestrated by treating VSMCs with 50 μg/mL Nys for 30 min. In some experi-
ments, after MCD treatment, cholesterol was reloaded with cholesterol:MCD (1–10 mmol/L) complex.
Immunoblotting. Total or fractionated proteins from VSMCs were separated by electrophoresis on a poly-
acrylamide gel, transferred onto a nitrocellulose membrane and probed with primary antibodies. Horseradish 
peroxidase-conjugated secondary antibodies were visualised by Azure c300 Western Blot Chemiluminescent 
Blot Imaging System and fluorescent-conjugated secondary antibodies were visualised by infrared laser scanner. 
Bands were quantified densitometrically with either ImageJ (https ://image j.nih.gov/ij/) or Image Studio Lite 
software from LI-COR.
Co‑immunoprecipitation and immunoblotting. Immunoprecipitation was performed on 200–500 μg 
protein lysates from VSMCs using specific primary antibodies as previously  described76. Immunoprecipitates 
were resolved in SDS–polyacrylamide gels. The following antibodies were used for immunoprecipitation (IP): 
anti-mouse Cav-1 (Bd Biosciences), anti-rabbit Total DJ1 (Abcam), anti-rabbit Nox5 (a generous gift from Pro-
fessor William Nauseef) and anti-goat Nox1 (Sigma-Aldrich). For Cav-1 and DJ1 IP, the immunoblottings were 
performed with anti- rabbit Cav-1 (Cell Signaling, 3267), anti-rabbit Nox1 (Sigma-Aldrich, SAB4200097), anti-
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rabbit Nox5 and anti-rabbit DJ1. For Nox5 IP, the immunoblottings were performed with anti-mouse Cav-1, 
anti-rabbit DJ1 and anti-rabbit Nox5. For Nox 1 IP, the immunoblottings were performed with anti-mouse 
Cav-1, anti-rabbit DJ1 and anti-rabbit Nox1. WB Optima A or B or C or F detection systems (Santa Cruz Bio-
technology, sc-4503 or sc-45038 or sc-45039 or sc-45040 respectively) were used to prevent interference of IgG 
chains in the immunoblot assays.
Immunocytochemistry. Human VSMCs were cultured on sterile glass coverslips, fixed in ice-cold 100% 
methanol for 5 min, blocked with 3% Bovine Serum Albumin (BSA) and incubated with primary antibodies 
overnight at 4 °C. Proteins were detected with Alexa Fluor secondary antibodies and slides were mounted in 
ProLong Gold anti-fade mounting media containing DAPI (Life technologies) overnight at RT. Fluorescence 
imaging was recorded in an Axiovert 200M microscope with a laser scanning module LSM 510 (Carl Zeiss AG, 
Heidelberg, Germany).
Hydrogen peroxide measurement—Amplex Red Assay. Hydrogen peroxide production in VSMC 
lysate was measured using the horseradish persoxidase-linked Amplex Red™ Hydrogen Peroxide/Peroxidase 
Assay Kit according to manufacturer’s instructions (Life Technologies, Paisley, UK).
Lucigenin‑enhanced chemiluminescence. The lucigenin-enhanced chemiluminescence assay was 
used to assess NAD(P)H-dependent superoxide anion  (O2−) production in VSMC homogenates as previously 
 described39.
Cav‑1, Nox5 and p22phox downregulation with siRNA. Human VSMCs were transfected with 
10 nmol/L of Cav-1 siRNA (Silencer® Select siRNA, Thermo Fischer Scientific), 20 nmol/L of p22phox siRNA 
(Stealth RNAi™ siRNA, Thermo Fischer Scientific) or 50 nmol/L of Nox5 siRNA (Stealth RNAi™ siRNA, Thermo 
Fischer Scientific) complexed with Lipofectamine™ RNAiMAX (Thermo Fischer Scientific). A sequence not 
homologous to any gene in the vertebrate transcriptome was used as control siRNA (Stealth RNAi™ siRNA 
Negative Control Lo GC, Thermo Fischer Scientific).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Software Inc, 
San Diego, CA, USA). All data are expressed as mean ± SEM. Statistical comparisons were made with one-way 
ANOVA followed by Newman–Keuls test or 2-tailed Student’s t test as appropriate. P < 0.05 was considered 
statistically significant.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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